- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00213798
Detection of Plasma DNA in Non Small Cell and Small Cell Lung Cancer Patients
December 15, 2025 updated by: University Hospital, Strasbourg, France
Detection of Plasma DNA by Allelotyping in Non Small Cell and Small Cell Lung Cancer Patients. Evolution During Treatment and Follow-up.
The majority of lung cancer patients have a tumor-derived genetic alteration in circulating plasma DNA that could be exploited as a diagnostic tool.
The aim of this study is to evaluate if plasma DNA can be used as a valuable non invasive test to monitor disease progression without assessing the tumor.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
200
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Strasbourg, France, 67091
- Service de Chirurgie Thoracique, Hôpital Civil
-
Strasbourg, France, 67098
- Service de Pneumologie, Hôpital de Hautepierre
-
Strasbourg, France, 67000
- Service de Pneumologie, Hôpital Lyautey
-
Strasbourg, France, 67091
- Service de Pneumologie, Hôpital Civil
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Presence of lung tumor to use fiberoscopy or surgical intervention for diagnosis.
- No lung instability.
- Individuals give all informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Michèle BEAU-FALLER, MD, Service de Pneumologie, Hôpital de Hautepierre
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2003
Study Completion (Actual)
August 1, 2011
Study Registration Dates
First Submitted
September 13, 2005
First Submitted That Met QC Criteria
September 13, 2005
First Posted (Estimated)
September 21, 2005
Study Record Updates
Last Update Posted (Estimated)
December 22, 2025
Last Update Submitted That Met QC Criteria
December 15, 2025
Last Verified
December 1, 2025
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2731
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Small Cell Lung Cancer
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
Royal Marsden NHS Foundation TrustUniversity of Cambridge; Royal Brompton & Harefield NHS Foundation Trust; Institute... and other collaboratorsRecruitingNon Small Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer | Locally Advanced NSCLC - Non-Small Cell Lung Cancer | Oncogene-addicted Non Small Cell Lung Cancer | Early-stage Operable Non Small Cell Lung Cancer | Stage 2/3 Operable Non Small Cell Lung CancerUnited Kingdom
-
PfizerRecruitingLung Neoplasms | Small Cell Lung Cancer | Carcinoma, Small Cell Lung | Small Cell Lung Cancer ( SCLC ) | Transformed Small Cell Lung Cancer | Small Cell Cancer Of The LungUnited States, Japan
-
Shanghai Chest HospitalRecruitingSmall Cell Lung Carcinoma | Small-cell Lung Cancer | Small Cell Lung Cancer Limited Stage | Small Cell Lung Cancer Extensive Stage | Small Cell Lung Cancer, Combined TypeChina
-
National Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung CancerUnited States
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
Jiangxi Provincial People's HopitalNot yet recruitingNon-Small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage IIIB | Non-small Cell Lung Cancer Stage IV | Non-small Cell Lung Cancer RecurrentChina
Clinical Trials on Biopsy samples
-
Assistance Publique Hopitaux De MarseilleSuspendedAortic Valve Regurgitation AcquiredFrance
-
Technion, Israel Institute of TechnologyRambam Health Care CampusUnknown
-
Assistance Publique - Hôpitaux de ParisCompletedAutosomal Recessive Congenital Ichthyosis | Epidermolytic IchthyosisFrance
-
The Christie NHS Foundation TrustAstraZenecaCompletedNon-Small Cell Lung CancerUnited Kingdom
-
Assistance Publique - Hôpitaux de ParisSociété de Dermatologie FrançaiseNot yet recruiting
-
Assistance Publique Hopitaux De MarseilleUnknown
-
Institut National de la Santé Et de la Recherche...Recruiting
-
Assistance Publique Hopitaux De MarseilleActive, not recruitingNon-small Cell Lung Cancer PatientsFrance
-
University of OxfordChiangrai Prachanukroh HospitalCompleted
-
European Organisation for Research and Treatment...TerminatedBreast CancerBelgium, Netherlands